Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SKB264 in advanced or metastatic non-small cell lung cancer
NCT05816252Phase 2Active, not recruiting
- Sponsor
- KLUS Pharma
- Start
- Apr 2023
- Primary completion
- Jun 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 6
01
Overview
A Phase 2 trial of sacituzumab tirumotecan in non-small cell lung cancer (NSCLC), sponsored by KLUS Pharma. Started Apr 2023; status: active, not recruiting.
02
Drugs
sacituzumab tirumotecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05816252.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05816252.